UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Paul Mischel, M.D.

Specialty:

Pathology

General Information:

Gender:	Male
Language(s):	English

Affiliation(s):

Professor, Department of Pathology and Laboratory Medicine

Joint Professor, Department of Molecular and Medical Pharmacology

Physician, Department of Pathology and Laboratory Medicine, Surgical Pathology, Neuropathology

Physician, Department of Pathology and Laboratory Medicine, Surgical Pathology

Co-Director, Cancer Stem Cell Area, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research

Associate Director of Clinical Sciences, The Institute of Molecular Medicine

Member, Brain Research Institute

Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:	Research, Howard Hughes Medical Institute, 1996 - 1998 Neuropathology, UCLA School of Medicine, 1993 - 1995
Residency:	Anatomic and Clinical Pathology, UCLA School of Medicine, 1992 - 1996
Internship:	Psychiatry, UCLA Neuropsychiatric Hospital, 1991 - 1992
Medical Degree:	M.D., Cornell University Medical College, 1991

Certification(s):

Medical Board Certification(s):	Anatomic Pathology, American Board of Pathology, 1997 Neuropathology, American Board of Pathology, 1997

Contact Information:

Surgical Pathology:	(310) 794-9450 Information and referral
Neuropathology:	(310) 825-6191 Information and referral
Phone:	(310) 825-2783 Stacey Cush, Administrative Analyst (310) 794-7512 Mischel Lab (310) 794-5223 Paul Mischel, M.D.
E-mail:	pmischel@mednet.ucla.edu
Website:	http://www.mischellab.org

Scientific Interest(s):

Glioblastoma is the most common malignant primary brain tumor in adults, and is among the most lethal of all cancers. Numerous new therapies hold great promise for the treatment of glioblastoma patients, but the chief challenge is to determine which treatment is most likely to benefit an individual patient. The overall goal of Dr. Paul Mischel's work is to identify and refine molecular subclasses and to identify new targets that can be used to guide patient therapy.

Selected Cancer-Related Publications:

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Yongkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008; 5(1):e8.

Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel PS. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A. 2006; 103(46): 17402-7.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Res. 2006; 66(16): 7864-7869.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353(19): 2012-24.

Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003; 63(11): 2742-6.